Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
Sep 24, 2018Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate CancerResults from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs 14.7 months for men who received placebo plus ADT(1)
Sep 21, 2018Bill and Giuliana Rancic to Lend Expertise, Passion and Personal Cancer Experience to Inspire Fellow Entrepreneurs
- Sep 14, 2018--Additional marketing award received for Best Video/TV Campaign--
Sep 12, 2018Winner Will Attend Live Taping of ABC's "Dancing with the Stars"
Aug 22, 2018Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate CancerAmendments accelerate anticipated primary completion dates for both ARCHES and EMBARK trials